InDevR Launches Automated Hemagglutination Analysis System for Improved Vaccine Characterization
Break-Through Cypher One System Fully Automates and Standardizes Analysis of Hemagglutination and Hemagglutination Inhibition Assays
BOULDER, CO–(Marketwired – June 10, 2015) – InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, today announced the launch of the Cypher One™ system, an affordable instrument and software package that automates the interpretation of hemagglutination and hemagglutination inhibition assays.
Hemagglutination assays are widely used in serology and virology, with applications ranging from blood typing to vaccine efficacy. Currently, hemagglutination assays rely on subjective, manual interpretation, which can lead to significant variations in the measurement between technicians and laboratories. There are a number of industrial and government groups calling for improved standardization in vaccine characterization, e.g., Global Health Network’s CONSISE (https://consise.tghn.org/). In response to these initiatives, InDevR developed an optical analyzer with proprietary software to automate and standardize results interpretation.
Dr. Bin Lu, VP of Research and Development at Vivaldi Biosciences evaluated the Cypher One system in his lab. He commented: “Having trained others to read HA plates, I understand that subjective interpretation is a real problem. The Cypher One automated hemagglutination analyzer can eliminate subjectivity within an institution and has the potential to standardize interpretation of HA and HI assays across the vaccine industry.”
Amy Aspelund, Associate Scientist at Vivaldi Biosciences, added: “The digital image from Cypher One provides a traceable record of each experiment – a valuable feature that has been lacking in HA/HI assays.”
“While considered a gold standard method in vaccine immunogenicity studies, the reliability of the HI assay has suffered from a manual analysis process that lacks standardization,” said Kathy Rowlen, Chief Executive Officer of InDevR. “The Cypher One system typifies our dedication to support global initiatives to improve influenza vaccines, as well as our company’s mission to advance vaccine development and manufacturing through innovative analytical tools that provide superior results.”
Development of the Cypher One system was funded in part by a National Institutes of Health 2-year Phase 1 Small Business Innovation Research grant sponsored by the National Institute of Allergy and Infectious Diseases (R43 AI106054). The first commercial units are slated to ship in September of this year.
More information about the Cypher One system, including a free webinar on June 30 at 12 p.m. MT is available at: https://attendee.gotowebinar.com/register/4104933570022562562
InDevR has a demonstrated commitment to innovative solutions for the life science industry. With focus on enhancing vaccines and other biotherapeutics, InDevR has emerged as a leader in progressive new analytical technologies that enable accelerated development and manufacturing of these life-saving products. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.
HHS is not responsible for the contents of this release. The statements contained in this release do not constitute endorsement or recommendation by the U.S. Government or HHS.
Sales & Marketing Manager
Bioscribe, Inc. – Media Relations for InDevR